FDA Approves Braeburn’s Long-Acting Brixadi to Treat Opioid Use Disorder

FDA Approves Braeburn’s Long-Acting Brixadi to Treat Opioid Use DisorderFiercePharma
FDA Approves Braeburn’s Brixadi Injection to Treat Moderate to Severe Opioid Use DisorderPharmacy hours
Braeburn’s BRIXADI™ (Buprenorphine) Sustained-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use DisorderPR Newswire
Indivior’s Opvee Crosses FDA Finish Line, Adding New Overdose Lifesaving Option Amid Raging Opioid EpidemicFiercePharma
FDA approves buprenorphine injection for opioid use disorderMedscape
See full coverage on Google News

FDA Approves Braeburn’s Long-Acting Brixadi to Treat Opioid Use Disorder – FiercePharma